title: Neurofibromatosis type 1 and precocious puberty.
abstract: Since neurofibromatosis type 1 (NF1) is a well known cause of precocious puberty (PP), we reviewed 412 NF1 pediatric patients to evaluate the prevalence of PP, the association with optic pathway tumors (OPT), and other clinical, auxological and hormonal data. Thirty-one of 412 patients had OPT (7.5%), 10/412 PP (2.4%), and in seven of these PP was associated with OPT (7/31, 22.6%). OPT in patients with PP involved the chiasm in four patients, and the optic nerves alone in three patients. The age at the onset of puberty (or better at diagnosis) ranged from 5.2 to 7.5 yr in girls (n=6) and from 7.9 to 8.9 yr in boys (n=4). LHRH agonist therapy was used in only three children because in the others the predicted height at diagnosis was good, treatment was refused or the patients were referred to us too late. The three treated patients attained a final height within the familial range. In the untreated patients the progression of puberty was not too rapid and final height was slightly below the genetic target in four patients; however, three patients had a final height markedly below the familial range. In conclusion, the prevalence of PP is increased in children with NF1, and frequently but not exclusively is associated with OPT. Moreover, sexual precocity does not seem to be necessarily bound to chiasmatic OPT. Treatment seems to be useful in the children with younger age at the onset of puberty or with a progressive decline in predicted final height.
authors.affiliation: Adolescents and Neurofibromatosis Center, Department of Pediatrics, University of Parma, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Virdis
authors.forename: M
authors.initials: M
authors.lastname: Sigorini
authors.forename: A
authors.initials: A
authors.lastname: Laiolo
authors.forename: E
authors.initials: E
authors.lastname: Lorenzetti
authors.forename: M E
authors.initials: ME
authors.lastname: Street
authors.forename: A R
authors.initials: AR
authors.lastname: Villani
authors.forename: A
authors.initials: A
authors.lastname: Donadio
authors.forename: F
authors.initials: F
authors.lastname: Pisani
authors.forename: C
authors.initials: C
authors.lastname: Terzi
authors.forename: L
authors.initials: L
authors.lastname: Garavelli
mesh_terms: D000293:Adolescent; D000328:Adult; D001827:Body Height / Q000187:drug effects; D001932:Brain Neoplasms / Q000150:complications; D002648:Child; D002675:Child, Preschool; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009456:Neurofibromatosis 1 / Q000150:complications*; D019574:Optic Nerve Neoplasms / Q000150:complications; D011629:Puberty, Precocious / Q000188:drug therapy / Q000209:etiology*; D014795:Visual Pathways
chemical_list: D007987:Gonadotropin-Releasing Hormone